重要内容提示： 广东溢多利生物科技股份有限公司 2022 年第三季度报告 债券代码：123018 债券简称：溢利转债 股票代码：300381 股票简称：溢多利 公告编号：2022-096 广东溢多利生物科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 广东溢多利生物科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 广东溢多利生物科技股份有限公司 2022 年第三季度报告 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益 项目的情况说明 | | 本报告期 | 本报告期 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥753,881,379.40, a decrease of 13.46% compared to ¥871,145,680.75 in the same period last year[24]. - The net profit attributable to shareholders was ¥15,557,366.99, down 74.26% from ¥60,441,377.69 year-on-year[24]. - The net profit after deducting non-recurring gains and losses was -¥44,140,254.36, a decline of 181.44% compared to ¥54,198,469.66 in the previous year[24]. - The basic earnings per share decreased by 74.29% to ¥0.0317 from ¥0.1233 in the same period last year[24]. - The company's operating revenue decreased by 13.46% compared to the same period last year, primarily due to the sale of the pharmaceutical segment and fluctuations in the agricultural and animal husbandry industry[36]. - The net profit attributable to shareholders decreased by 74.26% year-on-year, influenced by the sale of pharmaceutical assets and rising costs of raw materials and energy[36]. - The company reported a net profit of 9,957,018 yuan for its subsidiary, Changsha Shiwai Technology Co., Ltd[88]. - The company reported a net profit of CNY 28,597,536.82 for the first half of 2022, down from CNY 77,131,610.12 in the same period of 2021[194]. - The company reported a significant increase in cash inflows from investment activities, totaling CNY 1,167,764,227.30, compared to CNY 18,598.00 in the first half of 2021[199]. Cash Flow and Investments - The net cash flow from operating activities increased by 118.51% to ¥259,719,135.99 from ¥118,858,939.19 in the same period last year[24]. - Cash flow from operating activities increased by 118.51% to ¥259,719,135.99, primarily due to reduced cash payments for goods[41]. - The cash and cash equivalents increased by 310.12% to ¥760,648,689.88, largely due to cash received from equity transfers[41]. - The company reported an investment income of ¥132,908,344.57, a dramatic increase of 11,394.49% attributed to the transfer of subsidiary equity[45]. - The company reported a significant transaction involving the sale of equity, contributing a net profit of 1,229 million yuan, which represents approximately 24.58% of the total net profit[82]. - The company reported a total investment of ¥590,993,963.36 for the reporting period, representing a significant increase of 219.98% compared to ¥184,698,360.88 in the same period last year[58]. - The company has ongoing projects with significant investments, including a biological enzyme production facility with an annual capacity of 20,000 tons[60]. Asset Management - Total assets decreased by 30.74% to ¥3,102,946,583.17 from ¥4,479,934,615.27 at the end of the previous year[24]. - The company's total assets as of the reporting date included fixed assets of ¥4,953,438.97 and intangible assets of ¥2,786,289.01, both subject to loan financing[56]. - The company's total assets were CNY 2,916,193,625.42 in the first half of 2022, down from CNY 3,087,246,032.65 in the same period of 2021[193]. - The company's equity decreased to CNY 2,827,906,384.76 from CNY 3,048,007,590.50, reflecting a decline of approximately 7.2%[187]. - The company reported a significant reduction in inventory, which fell to CNY 186,330,216.28 from CNY 992,450,259.82, a decrease of about 81.2%[185]. Business Strategy and Market Focus - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company is investing in multiple projects in biological enzyme preparations and animal nutrition, supported by national policies and market demand, but faces uncertainties due to macroeconomic changes and industry competition[6]. - The company is expanding its product offerings in active natural products and animal nutrition and health, expecting a recovery in profitability as the agricultural sector stabilizes[36]. - The company aims to become a benchmark enterprise in the global enzyme preparation industry and a leading enterprise in functional feed additives in China[38]. - The company plans to focus on the health sector, emphasizing the development of new biological products using modern biotechnology[90]. - The company aims to strengthen its core businesses in biological enzyme preparations, active natural products, and animal husbandry and health[90]. - The company is committed to developing new biological products and expanding its market presence in the health and nutrition sectors[83]. Risk Management - The company faces short-term performance fluctuation risks due to the sale of its pharmaceutical business assets, which accounted for 48.83% of revenue in 2021[5]. - The company reported a significant impact on actual profits due to macroeconomic slowdown, increased industry competition, and rising labor costs[72]. - The company has established a comprehensive internal control system to ensure the safety of its overseas assets, which include Victory Enzymes GmbH in Germany and a subsidiary in Macau[53]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[105]. Corporate Governance and Compliance - The company has committed to not engaging in any competitive activities with its subsidiaries, ensuring no conflicts of interest arise[110]. - The company guarantees that there are no significant violations or penalties related to environmental, safety, or quality regulations since its establishment[112]. - The company has pledged to disclose any potential conflicts of interest and ensure fair market practices in related transactions[111]. - The company has confirmed that it will not provide technical information or trade secrets to competitors[110]. - The company has established a long-term commitment to fulfill its obligations and ensure compliance with all relevant laws and regulations[111]. Shareholder Information - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., holds 30.97% of the shares, totaling 141,615,094 shares[158]. - The company has a total of 19,095 shareholders at the end of the reporting period[156]. - The company approved a share repurchase plan on May 17, 2022, with a total fund of no less than RMB 100 million and no more than RMB 200 million, at a maximum price of RMB 12.50 per share[153]. - As of June 30, 2022, the company repurchased a total of 5,135,800 shares, accounting for 1.05% of the total share capital, with a total transaction amount of RMB 49,870,166.62[154].

Financial Performance - The company's operating revenue decreased by 1.18% compared to the previous year[5]. - The net profit attributable to shareholders decreased by 173.53% year-on-year, primarily due to asset impairment losses, rising raw material and energy prices, and production limitations caused by power outages[5]. - The company's operating revenue for 2021 was ¥1,892,160,336.27, a decrease of 1.18% compared to ¥1,914,764,458.88 in 2020[19]. - The net profit attributable to shareholders was -¥118,910,123.08 in 2021, representing a decline of 173.53% from ¥161,706,004.11 in 2020[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥133,979,417.42, a decrease of 219.72% compared to ¥111,906,716.13 in 2020[19]. - The net cash flow from operating activities was ¥216,929,263.66, down 46.27% from ¥403,726,106.50 in 2020[19]. - The total assets at the end of 2021 were ¥4,479,934,615.27, a decrease of 4.12% from ¥4,672,225,564.65 at the end of 2020[19]. - The net assets attributable to shareholders decreased by 6.22% to ¥2,792,803,878.46 at the end of 2021 from ¥2,978,092,925.07 at the end of 2020[19]. - The basic earnings per share for 2021 was -¥0.2426, a decline of 169.89% from ¥0.3471 in 2020[19]. - The company reported a significant drop in quarterly net profit in Q4 2021, with a loss of -¥190,084,694.34 compared to profits in the first three quarters[22]. Strategic Initiatives - The company plans to sell assets related to its biopharmaceutical segment to alleviate operational burdens and enhance cash flow, which may lead to short-term performance fluctuations[5]. - The company is increasing its investment in the industrial enzyme sector, which is considered a blue ocean market, to maintain competitive advantages amid intensifying market competition[5]. - The company aims to become a leading enterprise in functional feed additives in China, leveraging nearly 30 years of accumulated customer channel advantages[34]. - The company is the largest supplier of feed enzymes in China and plans to expand its international presence to capture additional market share[34]. - The company is currently planning to divest its pharmaceutical business assets while continuing its operations in the biopharmaceutical and biomanufacturing sectors[35]. - The company plans to enhance its product offerings and expand market reach through ongoing research and development initiatives[45]. Market Trends and Demand - The company operates in the growing bioenzyme and steroid hormone raw material sectors, with increasing demand expected in downstream industries[29]. - The functional feed additive market in China grew from RMB 25.05 billion in 2009 to RMB 48.4 billion in 2017, with a CAGR of approximately 9%[31]. - The demand for functional feed additives is expected to increase due to the "antibiotic-free" trend, leading to accelerated industry consolidation and growth opportunities for companies with core technologies[31]. - The market for functional feed additives is expected to expand significantly following the implementation of the Ministry of Agriculture's 2019 announcement banning growth-promoting drug additives in feed[34]. Research and Development - The company has a strong focus on research and development, holding 227 invention patents and 5 new veterinary drug product certificates[42]. - Research and development expenses increased by 5.66%, attributed to new technology introductions and increased personnel costs[45]. - The number of R&D personnel grew by 9.65% to 409, with a higher proportion of staff holding bachelor's and master's degrees[66]. - The company is actively involved in research and development of new products and technologies in the biopharmaceutical sector[82]. Environmental Compliance - The company reported a total of 749.32 tons of hazardous waste collected and treated, with no exceedances of the approved discharge limits[171]. - The company’s total nitrogen discharge was 1.008 tons, which is below the regulatory limit of 40 mg/l[171]. - The company’s total phosphorus discharge was 0.144 tons, which is below the regulatory limit of 4 mg/l[171]. - The company has a wastewater treatment capacity of 4,000 tons per day, ensuring compliance with environmental standards[176]. - The company has established emergency response plans for environmental incidents, which have been filed with local environmental protection bureaus, and conducts regular training and drills to enhance response capabilities[181]. Governance and Management - The company has established a governance structure that complies with the requirements of the Company Law and the Shenzhen Stock Exchange regulations, ensuring effective management and risk control[113]. - The board of directors consists of 7 members, including 3 independent directors, and has established four specialized committees to enhance decision-making and oversight[114]. - The company maintains independence from its controlling shareholder in terms of business operations, personnel, assets, and financial management, ensuring no interference in its operations[117]. - The company has implemented a performance evaluation and incentive mechanism that aligns employee compensation with performance, promoting accountability among senior management[114]. - The company has a complete and independent financial management system, with dedicated accounting personnel and independent decision-making capabilities[117]. Shareholder Engagement - The company reported a cash dividend of 1.00 yuan per 10 shares, totaling 49,006,731.60 yuan, which accounted for 100% of the total profit distribution[151]. - The proposed profit distribution plan for 2021 includes a cash dividend of 1.00 RMB per 10 shares, totaling 49,006,731.60 RMB, which will not include stock dividends or capital reserve transfers[153]. - The company emphasizes shareholder rights protection by ensuring timely and accurate information disclosure in compliance with relevant laws and regulations[188]. - The company has a stable profit distribution policy and dividend plan to reward shareholders[188]. Employee Development - The company focuses on employee rights protection, providing various training programs to enhance employee skills and knowledge[189]. - The company conducted various online training courses during the reporting period to enhance employees' professional knowledge and skills[149]. - The total number of employees at the end of the reporting period was 2,807, including 435 at the parent company and 2,372 at major subsidiaries[146].

Financial Performance - The company's revenue for Q1 2022 was CNY 423,524,718.42, an increase of 6.57% compared to CNY 397,419,671.58 in the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 31,782,651.21, a decrease of 225.23% from a profit of CNY 25,379,143.78 in the previous year[4] - Total operating revenue for Q1 2022 was CNY 423,524,718.42, an increase of 6.3% compared to CNY 397,419,671.58 in the same period last year[20] - Net profit for Q1 2022 was a loss of CNY 26,818,163.79, compared to a profit of CNY 34,856,133.57 in Q1 2021[21] - The company reported a comprehensive income total of CNY -26,844,689.57 for Q1 2022, down from CNY 34,856,133.57 in the previous year[22] - Basic and diluted earnings per share for Q1 2022 were both CNY -0.0649, compared to CNY 0.0518 and CNY 0.0511 respectively in Q1 2021[22] Cash Flow - The net cash flow from operating activities increased by 81.48% to CNY 110,618,733.78, up from CNY 60,953,891.69 in the same period last year[4] - Cash inflow from operating activities was CNY 488,078,976.30 in Q1 2022, compared to CNY 423,530,749.89 in the same period last year[24] - Cash outflow from operating activities totaled CNY 377,460,242.52 in Q1 2022, an increase from CNY 362,576,858.20 in Q1 2021[24] - The net cash flow from investing activities was ¥180,684,992.34, a significant recovery from a negative cash flow of ¥79,495,187.00 in the same period last year[25] - Cash inflow from financing activities totaled ¥329,900,000.00, compared to ¥313,000,000.00 in Q1 2021, indicating a 5.8% increase[25] - The net cash flow from financing activities was negative at -¥104,538,178.62, contrasting with a positive cash flow of ¥1,616,608.43 in Q1 2021[25] - The total cash and cash equivalents at the end of Q1 2022 reached ¥438,443,224.76, up from ¥236,084,025.61 in Q1 2021, marking an increase of 85.6%[25] - The company reported cash inflow from the disposal of subsidiaries amounting to ¥202,574,000.00, which was not present in the previous year[25] - The cash outflow for the acquisition of fixed assets and intangible assets was ¥22,341,321.27, a decrease from ¥79,148,585.00 in Q1 2021, indicating a reduction of 71.8%[25] - The cash flow from financing activities included cash paid for debt repayment of ¥393,840,000.00, compared to ¥294,307,520.00 in Q1 2021, reflecting a 33.8% increase[25] - The impact of exchange rate changes on cash and cash equivalents was minimal, with a net effect of ¥1,982.73 in Q1 2022[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,559,922,469.13, reflecting a 1.79% increase from CNY 4,479,934,615.27 at the end of the previous year[4] - The company's total liabilities amounted to CNY 1,536,330,412.65 as of Q1 2022, compared to CNY 1,431,927,024.77 in the previous year[18] - Total equity attributable to shareholders was CNY 2,763,973,304.31 in Q1 2022, down from CNY 2,792,803,878.46 in Q1 2021[18] - The company reported a decrease in retained earnings to CNY 595,378,922.76 in Q1 2022 from CNY 627,161,573.96 in the previous year[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,526[12] - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., holds 30.97% of shares, totaling 151,767,378 shares, with 10,152,284 shares pledged[12] Operating Costs - Operating costs increased by 36.31% to CNY 312,995,478.94, primarily due to rising prices of chemical raw materials and fixed costs from new production facilities[8] - Total operating costs for Q1 2022 were CNY 455,142,026.86, up 26.5% from CNY 360,000,528.84 in Q1 2021[20] Other Income and Expenses - The company received government subsidies amounting to CNY 5,323,860.23, contributing to a 50.53% increase in other income[8] - The company reported a significant increase in other payables by 366.97% to CNY 179,605,480.97, mainly due to received deposits for the transfer of pharmaceutical segment equity[7] Stock and Incentive Plans - The company approved the sale of all assets related to its biopharmaceutical business, including shares of three subsidiaries[13] - The company adjusted the stock incentive plan, reducing the grant price from ¥5.06 to ¥4.99 per share[13] - The company granted 800,000 reserved shares to 22 incentive objects as part of the stock incentive plan[13] Audit Information - The company did not conduct an audit for the Q1 2022 report[26]

Financial Performance - The company's operating revenue decreased by 1.18% compared to the same period last year[4]. - The net profit attributable to shareholders decreased by 173.53% year-on-year, primarily due to asset impairment losses, rising raw material and energy prices, and production limitations caused by power outages[4]. - The company's operating revenue for 2021 was ¥1,892,160,336.27, a decrease of 1.18% compared to ¥1,914,764,458.88 in 2020[17]. - The net profit attributable to shareholders was -¥118,910,123.08, representing a decline of 173.53% from ¥161,706,004.11 in the previous year[17]. - The net cash flow from operating activities decreased by 46.27% to ¥216,929,263.66 from ¥403,726,106.50 in 2020[17]. - The total assets at the end of 2021 were ¥4,479,934,615.27, down 4.12% from ¥4,672,225,564.65 at the end of 2020[17]. - The company's basic earnings per share for 2021 was -¥0.2426, a decrease of 169.89% compared to ¥0.3471 in 2020[17]. - The weighted average return on equity was -4.10%, a decline of 10.04% from 5.94% in the previous year[17]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, with a figure of -¥133,979,417.42 for 2021[17]. - The company's revenue decreased by 1.18% compared to the previous year, while the net profit attributable to shareholders dropped by 173.53% due to various factors including impairment losses related to the vitamin B12 business[38]. Asset Management and Divestment - The company plans to divest assets related to its biopharmaceutical segment to alleviate operational burdens and enhance cash flow, aiming for faster industrial upgrades[4]. - The company is currently planning to divest its pharmaceutical business assets while continuing to operate in the biopharmaceutical and biomanufacturing sectors[33]. - The company plans to acquire minority stakes in subsidiaries to enhance its strategic position in the market[146]. Market Position and Industry Trends - The company is positioned in the growing bioenzyme preparation industry, which is expected to see stable high growth due to increasing demand from downstream industries[28]. - The steroid hormone raw material drug industry in China has become a global production center, with the country's annual output accounting for about one-third of the world's total[28]. - The functional feed additive market in China grew from RMB 25.05 billion in 2009 to RMB 48.4 billion in 2017, with a CAGR of approximately 9%[29]. - The demand for functional feed additives is expected to increase due to the "antibiotic-free" trend, leading to accelerated industry consolidation and growth opportunities for companies with core technologies[29]. - The company is the largest supplier of feed enzymes in China and aims to solidify its leading position while expanding internationally to capture new market shares[32]. - The market for antibiotic alternatives in feed additives is expected to grow significantly following the implementation of the Ministry of Agriculture's 2019 announcement prohibiting the use of growth-promoting drug additives[32]. Research and Development - The company has a strong focus on R&D, with 4 proprietary technologies, 11 core technologies, and 227 invention patents[40]. - Research and development expenses increased by 5.66% year-on-year, attributed to new technology introductions and increased personnel costs[43]. - The company is developing new products, including a new type of protease for cleaning products, which has completed experimental development and is in the sales phase[63]. - There are ongoing R&D projects aimed at optimizing enzyme production processes to reduce costs and enhance product competitiveness[63]. - The company has filed for 10 new patents in the last year, focusing on innovative biotechnological solutions[129]. Corporate Governance - The company has established a governance structure that complies with the requirements of the Company Law and the Shenzhen Stock Exchange regulations, ensuring effective internal control and risk management[115]. - The board of directors consists of 7 members, including 3 independent directors, and has established four specialized committees to enhance governance effectiveness[116]. - The company maintains independence from its controlling shareholder in terms of business operations, personnel, assets, and financial management, ensuring no interference in its operations[119]. - The company has implemented a performance evaluation and incentive mechanism for senior management, linking compensation to performance effectively[116]. - The company has a complete and independent financial management system, with dedicated accounting personnel and independent decision-making capabilities[119]. Environmental Responsibility - The company reported a total of 749.32 tons of hazardous waste generated, with a permitted discharge of 1477.5 tons per annum, and no instances of exceeding discharge limits[172]. - The concentration of non-methane total hydrocarbons was reported at 0.73 mg/l, well below the standard of 120 mg/l[172]. - The company has a total nitrogen discharge concentration of 7 mg/l, which is below the regulatory limit of 40 mg/l[172]. - The company has achieved a total COD discharge of 36.25 mg/L, significantly below the limit of 450 mg/L, with an annual total of 0.6406 tons[173]. - The company has engaged third-party services for hazardous waste disposal, ensuring compliance with environmental regulations[187]. Employee and Stakeholder Engagement - The company has established a performance evaluation system for senior management, ensuring that employee income is closely linked to work performance[150]. - The company conducted various online training sessions during the reporting period to enhance employees' professional knowledge and skills[151]. - The participation rate of investors in the 2021 annual general meeting was 36.76%, indicating a strong engagement from shareholders[120]. - The company emphasizes employee rights protection and implements various training programs to enhance employee skills[190]. - The company actively fulfills its corporate social responsibilities while creating value for shareholders[189]. Future Outlook - The company expects a revenue growth of 10% to 12% for the upcoming fiscal year, projecting revenues between 1.32 billion RMB and 1.344 billion RMB[129]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in sales in that region by 2023[129]. - Future guidance indicates a revenue growth target of 20% for the next fiscal year, aiming for 1.44 billion RMB[199]. - The company is exploring partnerships with local distributors to enhance supply chain efficiency, which is expected to reduce costs by 5%[200].

广东溢多利生物科技股份有限公司 2021 年第三季度报告 证券代码：300381 证券简称：溢多利 公告编号：2021-092 广东溢多利生物科技股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增减 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | | | 同期增减 | | 营业收入（元） | 417,374,900.24 | -18.70% | 1,288,520,581.00 | ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥871,145,680.75, a decrease of 5.06% compared to ¥917,554,527.33 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥60,441,377.69, down 13.05% from ¥69,512,111.84 in the previous year[21]. - The net profit after deducting non-recurring gains and losses increased by 6.55% to ¥54,198,469.66 from ¥50,865,689.57 year-on-year[21]. - The basic earnings per share decreased by 21.21% to ¥0.1233 from ¥0.1565 in the same period last year[21]. - The company reported a net cash flow from operating activities of ¥118,858,939.19, a decrease of 2.40% from ¥121,786,868.91 in the same period last year[21]. - The company's revenue for the reporting period was ¥871,145,680.75, a decrease of 5.06% compared to ¥917,554,527.33 in the same period last year, primarily due to the recovery of sales in the biopharmaceutical sector after the pandemic[44]. - The company's operating costs decreased by 16.23% to ¥497,818,430.66 from ¥594,285,158.79, indicating improved cost management[44]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,596,421,263.20, a decrease of 1.62% from ¥4,672,225,564.65 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased by 0.90% to ¥3,004,834,878.65 from ¥2,978,092,925.07 at the end of the previous year[21]. - The company's total assets at the end of the reporting period were ¥4,598,000,000, with cash and cash equivalents amounting to ¥223,636,042.74, a decrease from ¥303,095,521.39 at the end of the previous year[51]. - Long-term borrowings increased by 114.76% to ¥152,480,000.00, reflecting the company's increased financing needs[51]. - Accounts receivable decreased by 32.65% compared to the beginning of the year, totaling CNY 12,458,991.86[52]. - Prepayments increased by 44.21% compared to the beginning of the year, reaching CNY 37,362,807.80[52]. - Other receivables grew by 40.06% compared to the beginning of the year, amounting to CNY 47,544,762.95[52]. - Employee compensation payable decreased by 53.62% compared to the beginning of the year, totaling CNY 17,876,330.16[52]. - Tax payable decreased by 39.26% compared to the beginning of the year, amounting to CNY 15,259,885.09[52]. - Other payables decreased by 43.67% compared to the beginning of the year, totaling CNY 34,992,324.91[52]. - Current liabilities due within one year decreased by 94.18% compared to the beginning of the year, amounting to CNY 793,640.82[52]. - Other current liabilities decreased by 40.24% compared to the beginning of the year, totaling CNY 283,351.07[52]. Investments and Projects - The company has multiple ongoing investment projects in steroid hormone APIs, biological enzyme preparations, and functional feed additives, which are supported by national policies and have significant market demand[6]. - The company made a significant equity investment of 79,750,000 yuan in Changsha Shiyi Technology Co., Ltd., acquiring an 80% stake[58]. - The company established a new subsidiary, Macao Yiduo Li Co., Ltd., with an investment of 573,384 yuan, holding a 70% stake[58]. - The total investment in the annual production of 1,200 tons of steroid intermediates project reached 31,797,364 yuan, with a cumulative actual investment of 245,382,921 yuan, achieving 89.61% of the planned investment[61]. - The company has invested 5,929,789 yuan in the annual production of 20,000 tons of biological enzyme preparations, with a cumulative actual investment of 42,735,282 yuan, representing 40.22% of the planned investment[61]. - The investment in the annual production of 15,000 tons of food-grade biological enzyme preparations reached 19,591,574 yuan, with a cumulative actual investment of 159,530,000 yuan, achieving 89.20% of the planned investment[62]. - The company has not yet commenced production on several projects, including the biological enzyme preparations and steroid intermediates[61][62]. - The company is focusing on expanding its market presence through strategic investments and acquisitions in the biotechnology sector[75]. Market and Industry Position - The company focuses on the development, production, and sales of biological enzyme preparations, steroid hormone raw materials, and functional feed additives, targeting the biopharmaceutical and agricultural sectors[29]. - The biological enzyme products include feed enzymes, energy enzymes, food enzymes, paper-making enzymes, textile enzymes, and environmental enzymes, which are essential for various industrial applications[30]. - The steroid hormone raw materials primarily consist of corticosteroid and reproductive health system drugs, with key products including prednisone and dexamethasone, which are used in treating various medical conditions[31]. - The functional feed additives have seen continuous growth, driven by the national policy promoting antibiotic-free farming, indicating a broad market prospect[32]. - The company has become a major supplier in the Chinese feed enzyme market and aims to solidify its leading position domestically while expanding internationally[38]. - The company is positioned as a core enterprise in the global steroid hormone raw material market, with a focus on technological innovation in key intermediates[38]. - The domestic steroid hormone raw material production capacity accounts for approximately one-third of the world's total output, with the company being a significant player in this sector[37]. - The functional feed additives market is expected to grow due to the ban on growth-promoting antibiotics, leading to increased demand for alternative products[39]. - The company has established itself as the first professional producer of biocatalysts in China and the largest in Asia, actively participating in setting national and industry standards[40]. - The aging population in China is expected to drive the demand for healthcare and raw materials, contributing to the growth of the steroid hormone market[37]. Environmental Compliance - Hunan Xinhai Biological Pharmaceutical Co., Ltd. is classified as a key pollutant discharge unit by the environmental protection department[104]. - The total discharge of hazardous waste by Hunan Hongying Biological Technology Co., Ltd. is 58.9 tons, with a maximum allowable limit of 120 tons[105]. - The company operates a wastewater treatment facility capable of processing 4,000 tons of wastewater daily, ensuring compliance with discharge standards[111]. - The company has established a contract for hazardous waste treatment, which is regularly monitored and managed by qualified third-party services[110]. - The company has implemented regular maintenance for air pollution control facilities, with no instances of exceeding emission standards reported[113]. - The company has achieved stable operation of all pollution control facilities, with all pollutants meeting discharge standards[114]. - The company conducts monthly sampling and testing of wastewater by a qualified third-party testing company, ensuring compliance with environmental regulations[113]. - The company has installed noise reduction measures for equipment, minimizing environmental impact[113]. - The company has a comprehensive emergency response plan for environmental incidents, which has been filed with local environmental protection bureaus[124][125][126][127]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[136]. Corporate Governance and Shareholder Relations - The company plans to implement a stock incentive plan, granting 8 million restricted stocks, with an initial grant of 7.2 million shares[99]. - The company will not distribute cash dividends or bonus shares for the half-year period[97]. - The company has established a stable profit distribution policy and dividend plan to ensure reasonable returns for investors[143]. - The company has no significant litigation or arbitration matters during the reporting period, indicating a stable legal environment[153]. - The company has not engaged in any major related party transactions during the reporting period, ensuring transparency in financial dealings[156]. - The company has 490,062,472 total shares outstanding, with 96.02% being unrestricted shares[176]. - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., holds 30.97% of the shares, totaling 151,767,378 shares[179]. - The company has not reported any significant changes in the financial condition or credit status of its guarantors during the reporting period[197]. Financial Management - The current ratio improved to 200.14%, up from 181.92%, reflecting an increase of 18.22%[200]. - The interest coverage ratio increased to 5.95, representing a 21.18% improvement from 4.91[200]. - The cash interest coverage ratio rose to 8.36, marking a 19.94% increase from 6.97[200]. - The EBITDA interest coverage ratio improved significantly to 10.3, an increase of 28.27% from 8.03[200]. - The debt-to-asset ratio decreased to 29.00%, down by 1.16% from the previous year[200]. - The quick ratio increased to 85.47%, up from 82.24%, reflecting a 3.23% improvement[200]. - The company maintained a loan repayment rate of 100.00%, consistent with the previous year[200]. - The interest payment ratio also remained stable at 100.00%, unchanged from the prior year[200]. - The EBITDA to total debt ratio improved to 13.21%, an increase of 0.80% from 12.41%[200].

Financial Performance - The company's operating revenue for Q1 2021 was ¥397,419,671.58, a decrease of 1.27% compared to ¥402,535,465.00 in the same period last year[7] - Net profit attributable to shareholders increased by 35.38% to ¥25,379,143.78 from ¥18,746,963.62 year-on-year[7] - The net profit after deducting non-recurring gains and losses rose by 79.01% to ¥23,429,235.81 compared to ¥13,088,046.01 in the previous year[7] - Basic earnings per share increased by 21.60% to ¥0.0518 from ¥0.0426 year-on-year[7] - Net profit increased by 18,014,986.26 CNY, a growth of 106.46%, driven by significant sales revenue growth of biological enzyme products and functional feed additives[17] - Net profit for Q1 2021 was CNY 34,856,133.57, compared to CNY 16,921,427.93 in the same period last year, representing a significant increase[46] - The total comprehensive income for the period was CNY 22,725,639.17, compared to CNY 14,838,681.35 in the same period last year, reflecting a growth of 53.3%[51] Cash Flow - The net cash flow from operating activities surged by 107.54% to ¥60,953,891.69 from ¥29,369,882.06 in the same period last year[7] - Operating cash flow net amount was 60,953,891.69 CNY, a year-on-year increase of 107.54%, attributed to increased cash received from sales[18] - Total cash inflow from operating activities was CNY 423,530,749.89, compared to CNY 361,067,109.34 in the prior year, representing an increase of 17.3%[54] - The company reported a cash outflow from investing activities of CNY 79,505,785.00, which is an increase from CNY 43,609,447.92 in the previous year[54] - The net cash flow from financing activities was CNY 1,616,608.43, a decrease from CNY 155,472,762.26 in the same period last year[55] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,680,943,536.95, a slight increase of 0.19% from ¥4,672,225,564.65 at the end of the previous year[7] - The company's current assets decreased to CNY 2,058,029,299.04 from CNY 2,083,031,416.41, primarily due to a reduction in cash and cash equivalents[36][37] - The total liabilities decreased to CNY 1,370,489,495.51 from CNY 1,409,302,025.06, indicating improved financial stability[38][39] - The company's equity attributable to shareholders increased to CNY 3,016,146,437.13 from CNY 2,978,092,925.07, reflecting a growth of approximately 1.9%[39] Shareholder Information - The company reported a total of 24,451 common shareholders at the end of the reporting period[10] - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., held 30.97% of the shares, amounting to 151,767,378 shares[10] Investment and Projects - The investment in the Inner Mongolia Yiduoli enzyme preparation project reached 99.80% completion with an investment of 9,480.7 million[25] - The marketing service network construction project has utilized 1,944.9 million, achieving 77.80% of its planned investment[25] - The acquisition of Hunan Hongying Biotechnology Co., Ltd. was completed with a cash consideration of 5,650 million, achieving 100% completion[26] - The company plans to adjust the investment of 1 billion CNY (100 million) from the original "annual production of 20,000 tons of biological enzyme preparation project" to the "annual production of 1,200 tons of steroid drugs and intermediates project"[27] Financial Management - The company has no violations regarding external guarantees during the reporting period[30] - There are no non-operating fund occupations by controlling shareholders or their affiliates during the reporting period[31] - The company reported a significant reduction in short-term borrowings, which decreased to CNY 570,762,500.00 from CNY 635,884,185.00, a decline of approximately 10.2%[38] Research and Development - Research and development expenses increased to CNY 26,180,795.15 from CNY 20,884,099.44, highlighting a focus on innovation[45] Miscellaneous - The company did not engage in any repurchase transactions during the reporting period[11] - The company did not undergo an audit for the first quarter report[60] - The report indicates that the new leasing standards were not applicable for the current period[59]

Financial Performance - The company's operating revenue for 2020 was CNY 1,914,764,458.88, a decrease of 6.51% compared to CNY 2,048,133,404.03 in 2019[15] - The net profit attributable to shareholders for 2020 was CNY 161,706,004.11, an increase of 26.81% from CNY 127,522,059.24 in 2019[15] - The net cash flow from operating activities was CNY 403,726,106.50, down 8.69% from CNY 442,165,361.20 in the previous year[15] - The basic earnings per share for 2020 was CNY 0.3471, reflecting a growth of 13.65% compared to CNY 0.3054 in 2019[15] - Total assets at the end of 2020 amounted to CNY 4,672,225,564.65, representing a 3.41% increase from CNY 4,518,083,187.45 in 2019[15] - The net assets attributable to shareholders increased by 20.80% to CNY 2,978,092,925.07 from CNY 2,465,213,969.38 in 2019[15] - The company reported a diluted earnings per share of CNY 0.3456, which is a 14.86% increase from CNY 0.3009 in 2019[15] - The weighted average return on net assets for 2020 was 5.94%, up from 5.63% in 2019[15] Revenue Breakdown - The revenue from steroid hormone raw materials accounted for 56.78% of total operating revenue, while the gross profit margin was 45.96%[52] - The revenue from bioenzyme preparations represented 29.02% of total operating revenue, with a gross profit margin of 34.94%[52] - Functional feed additives contributed 10.33% to total operating revenue, with a gross profit margin of 17.02%[52] - The biopharmaceutical sector generated CNY 1.09 billion, accounting for 56.78% of total revenue, down 9.92% from the previous year[55] - Revenue from the biological products sector increased by 9.01% to CNY 555.66 million, representing 29.02% of total revenue[55] - The functional feed additives segment saw a significant growth of 72.68%, with revenue reaching CNY 197.79 million[55] Investment and R&D - R&D expenses increased by 10.02% year-on-year, primarily due to the amortization of intangible assets from foreign technology introduction and increased salaries for R&D personnel[52] - The company is focusing on investment projects in biomedicine, enzyme preparations, and functional feed additives, supported by strong market demand and national policies[4] - The company plans to enhance its product offerings in the bio-pharmaceutical sector, including the development of new products such as fluocinolone and methylprednisolone[50] - The company is focusing on the research and development of antiviral drugs and related products[90] - The company has committed to invest RMB 20,000 million in the enzyme preparation project, with 99.80% of the investment completed by June 30, 2020[99] Market Expansion and Strategy - The company aims to expand its market presence by providing comprehensive biotechnology solutions and developing new products in response to industry demands[25] - The company is focusing on expanding its market presence through increased promotion of new products and optimizing the cost structure of existing products[30] - The company has established a comprehensive marketing network covering over 60 countries and regions, with more than 2,300 high-quality direct sales customers[44] - The company is actively pursuing mergers and acquisitions to strengthen its market position and expand its product offerings[101] - The company has strengthened its overseas market expansion efforts, conducting over 200 online meetings with international clients during the pandemic[49] Environmental Responsibility - The company is focused on improving its environmental performance and compliance with regulatory standards in its operations[181] - The company has a commitment to environmental protection, adhering to national standards for pollutant discharge[179] - The company has established a long-term management and supervision mechanism for environmental responsibility[151] - The company has achieved a desulfurization efficiency of 96% and a dust removal efficiency of 99% in its emissions control systems[191] - The company has a noise reduction strategy in place, utilizing sound-absorbing materials and centralized equipment to minimize environmental impact[188] Shareholder Returns - The company plans to distribute a cash dividend of CNY 0.7 per 10 shares, based on a total of 490,058,748 shares[4] - The cash dividend accounted for 100% of the total distributable profit of RMB 161,706,004.11[128] - The company maintained a consistent dividend policy over the past three years, with previous distributions of RMB 0.60 per share in 2018 and 2019[129] - The company’s profit distribution plan was approved by the board and independent directors, ensuring shareholder interests were protected[127] - In 2020, the cash dividend amount for the company was 34,304,112.36, representing 21.21% of the net profit attributable to ordinary shareholders[131] Compliance and Governance - The company has not faced any administrative penalties or criminal punishments related to the securities market in the past five years[135] - The company is committed to avoiding any illegal occupation of assets and ensuring fair market practices in related transactions[135] - The company has ongoing commitments regarding competition and related transactions, ensuring no direct or indirect competition with its business[132] - The company has established long-term business relationships with raw material processing enterprises and manufacturers in the US, Japan, India, and Germany, with over 80% of its sales coming from exports[112] - The company has received independent opinions from its independent directors and financial advisors regarding the use of fundraising for project adjustments and replacements[103]

Financial Performance - Operating revenue for the reporting period was ¥513,356,547.37, a decrease of 6.16% year-on-year[7] - Net profit attributable to shareholders of the listed company was ¥53,508,543.51, representing a growth of 21.23% compared to the same period last year[7] - The net profit after deducting non-recurring gains and losses was ¥48,392,200.16, up 16.78% year-on-year[7] - Basic earnings per share increased by 7.20% to ¥0.1146[7] - The company's operating profit for Q3 2020 was approximately ¥78.70 million, an increase of 21.3% compared to ¥64.86 million in the same period last year[42] - Net profit for Q3 2020 reached ¥69.06 million, up 18.3% from ¥58.39 million in Q3 2019[42] - The total comprehensive income for Q3 2020 was ¥69.06 million, compared to ¥58.39 million in the same quarter last year, marking a growth of 18.3%[43] - The total profit for the third quarter was CNY 173.13 million, an increase of 41.3% compared to CNY 122.49 million in the same period last year[49] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,591,859,517.46, an increase of 1.63% compared to the end of the previous year[7] - The company's total liabilities decreased to CNY 1,472,348,019.32 from CNY 1,789,323,009.37, indicating a reduction of approximately 17.7%[35] - Total assets as of September 30, 2020, amounted to CNY 4,591,859,517.46, compared to CNY 4,518,083,187.45 at the end of 2019[35] - Total liabilities reached CNY 1,789,323,009.37, with current liabilities at CNY 1,115,075,326.87 and non-current liabilities at CNY 674,247,682.50[64] - The total liabilities to equity ratio stands at approximately 0.66, indicating a balanced capital structure[65] Cash Flow - The net cash flow from operating activities was ¥91,209,626.94, an increase of 28.73% compared to the same period last year[7] - Cash generated from operating activities decreased by 13.12% to ¥212,996,495.85, due to increased cash payments for goods and services[16] - The cash inflow from operating activities amounted to CNY 1,366,513,180.76, an increase from CNY 1,205,116,055.13 in the previous period, representing a growth of approximately 13.36%[56] - The cash outflow for purchasing goods and services was CNY 697,391,667.96, compared to CNY 531,501,094.97, reflecting an increase of approximately 31.23%[56] - The net cash flow from financing activities was -CNY 21,206,077.71, an improvement from -CNY 661,373,167.20, indicating a positive change of about 96.80%[57] Investments - Long-term equity investments increased by 297.97% to ¥9,164,870.30, primarily due to additional investments in subsidiaries[15] - Investment income surged by 488.52% to ¥4,506,326.97, mainly from the disposal of equity in a subsidiary[16] - The company reported a significant increase in long-term equity investments, rising to CNY 9.16 million from CNY 2.30 million at the end of 2019[33] Shareholder Information - Net assets attributable to shareholders of the listed company increased by 15.56% to ¥2,848,798,397.64[7] - The total number of ordinary shareholders at the end of the reporting period was 29,159[11] - The company's cash dividend policy was strictly followed, with a total cash dividend distribution of CNY 26.39 million for the year 2019, amounting to CNY 0.60 per 10 shares[23] Regulatory and Compliance - The company received government subsidies amounting to ¥32,333,922.47 during the reporting period[8] - The company’s board approved the termination of a previous private placement plan due to regulatory changes[17] - The company received approval from the China Securities Regulatory Commission for the registration of a stock issuance to specific investors on October 12, 2020[21] - The company implemented the new revenue recognition standard starting January 1, 2020, affecting the classification of contract liabilities[70] Research and Development - Research and development expenses for the quarter were CNY 30,786,921.36, up from CNY 28,861,888.10 in the previous period[41] - The company's R&D expenses for Q3 2020 were ¥8.25 million, up from ¥7.28 million in Q3 2019, indicating a focus on innovation[45] - Research and development expenses increased to CNY 21.55 million, up 26.3% from CNY 17.05 million in the previous year[51]